MedTrace Logo

Comparison of Bimatoprost and Latanoprost in Patients With Chronic Angle-Closure Glaucoma: A Randomized Cross-Over Study

NCT00567788 · Status: UNKNOWN · Phase: NA · Type: INTERVENTIONAL · Enrollment: 60

Last updated 2007-12-05

No results posted yet for this study

Summary

This is a randomized observer-masked cross-over study to compare the intraocular pressure (IOP) reducing effect of latanoprost with bimatoprost in subjects with chronic angle closure glaucoma (CACG) with raised IOP. Study subjects will be randomized to receive either latanoprost once daily or bimatoprost once daily for 6 weeks, after which they will be crossed over to the other medication for another 6 weeks. The IOP-reducing effect of the medications will be assessed by the reduction in IOP after each medication compared to baseline. The study will be carried out in at least 2 Singapore hospitals.

Conditions

  • Glaucoma, Angle-Closure

Interventions

DRUG

Latanoprost-Bimatoprost

latanoprost 0.005% once daily followed by bimatoprost 0.03%

DRUG

Bimatoporost-Latanoprost

bimatoprost 0.03% once daily followed by latanoprost 0.005%

Sponsors & Collaborators

  • Allergan

    collaborator INDUSTRY

  • Singapore National Eye Centre

    lead OTHER_GOV

Principal Investigators

  • Tin Aung · SNEC

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
40 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2006-07-31
Completion
2008-07-31

Countries

  • Singapore

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00567788 on ClinicalTrials.gov